US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio ASA publishes Annual Report for 2018

Bergen, Norway, 20 February 2019 – The Board of Directors of BerGenBio ASA (OSE:BGBIO) has today approved the Company's Annual Report for 2018 including the complete 2018 Annual Accounts with notes. The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports. -End-About BerGenBio ASA  BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers.  The company’s proprietary lead candidate, bemcentinib, is

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

Important progress made in 2018: · PoC for bemcentinib reported in multiple cancer indications · AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 · Increasing confidence in bemcentinib safety profile with more than 250 patients dosedBergen, Norway, 12 February 2019 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2018. A presentation of the results by

BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS

· Phase II monotherapy study of bemcentinib in high-risk MDS & AML · Will enrol up to 43 patients at leading MDS centres across Europe · Investigator sponsored trial led by Prof. Uwe PlatzbeckerBergen, Norway, Jan 4th 2019 - BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who have failed first-line treatment with hypomethylating agents. The trial may also enrol a proportion of

BerGenBio ASA: Results for the Third Quarter 2018

· Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients · Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, encouraging efficacy reported in combination trial with docetaxel in later line patients · Pipeline update: IND filed for AXL antibody BGB149Bergen, Norway, 13 November 2018 – BerGenBio ASA (OSE:

BerGenBio ASA: Results for the Second Quarter and First Half 2018

· Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib (BGB324) · Advanced lung cancer (NSCLC): First stage fully recruited, and first efficacy endpoint met in phase II trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® · Advanced leukaemia (AML/MDS): Encouraging bemcentinib single agent activity in hard to treat relapsed / refractory (R/R) leukaemia · Pipeline update: AXL antibody preparing for Phase I clinical trialBergen, Norway, 21 August 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage

BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA

Bergen, Norway, 18 May 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS) at the 23rd Congress of the European Hematology Association (EHA) in Stockholm (14-17 June 2018). Abstracts are now available online at https://ehaweb.org and details of the presentations are below. The posters presented at EHA will be made available on www.bergenbio.com in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media